Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 adjunctive XEN1101 study in focal-onset seizures
jRCT2021260009Phase 3Recruiting
- Sponsor
- Xenon Pharmaceuticals
- Start
- Sep 2026
- Modality
- Small Molecules
01
Overview
Phase 3, randomised, double-blind trial of azetukalner in Focal Onset Epilepsy and Focal onset seizure (3 arms), sponsored by Xenon Pharmaceuticals. Primary endpoint: Median percent change in focal seizure frequency. Started Sep 2026; status: recruiting.
02
Drugs
azetukalner
03
Conditions
Focal Onset EpilepsyFocal onset seizure
Beyond the preview
Go deeper on jRCT2021260009.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2021260009.